Hamilton BioVentures

Hamilton BioVentures is a California-based venture capital firm established in 2000, managing $100 million in assets. The firm focuses on investing in early-stage biotechnology companies in the United States, particularly those developing innovative treatments in biopharmaceuticals and medical devices aimed at addressing significant human diseases and medical conditions. Hamilton BioVentures primarily provides direct equity investments to talented entrepreneurs on the West Coast who are working to bring new life science technologies to market.

Kerry Dance

Managing Director

8 past transactions

Splash Pharmaceuticals

Series D in 2018
Splash Pharmaceuticals, Inc. is a clinical stage oncology company based in San Diego, California, focused on developing innovative cancer therapies. Founded in 2001, the company is dedicated to creating novel agents that target the cell-surface glycoprotein CD44, aiming to provide significant and lasting responses in patients with various solid tumors. Its lead product, SPL-108, has shown promise in demonstrating anti-angiogenic and anti-metastatic properties, as well as enhancing the effectiveness of traditional chemotherapy agents. In addition to its oncology focus, Splash is also exploring therapies for arthritis. The company is actively seeking partnerships with pharmaceutical firms to expedite the advancement of its clinical programs.

PhotoThera

Series D in 2009
PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

Ceregene

Series C in 2007
Ceregene is a privately held biotechnology company based in San Diego, specializing in the treatment of major neurodegenerative disorders through the delivery of nervous system growth factors. The company's clinical programs feature CERE-110, an AAV2-based vector expressing nerve growth factor, which is set to enter Phase 2 studies for Alzheimer's disease. Additionally, CERE-120 has recently completed a Phase 2 trial for Parkinson's disease and is under evaluation for future development. Ceregene is also advancing two other treatments, CERE-135 and CERE-140, which are in preclinical stages targeting amyotrophic lateral sclerosis (ALS) and ocular diseases, respectively.

Transcept Pharmaceuticals

Series D in 2007
Transcept Pharmaceuticals, Inc. is engaged in the development of proprietary products aimed at addressing therapeutic needs in neuroscience. The company utilizes a unique delivery system that enhances drug penetration and accelerates their onset of action. Transcept is focused on creating rapid-acting formulations of several established pharmaceuticals, seeking to improve patient outcomes in various neurological conditions. The company has attracted investment from notable firms, including Montreaux Equity Partners, Peninsula Equity Partners, Vivo Ventures, New Leaf Venture Partners, Interwest Partners, and New Enterprise Associates, supporting its ongoing research and development efforts.

Kemia

Series C in 2006
Kémia operates as a pharmaceutical company. The company discovers and develops small molecule therapeutics. It offers allosteric kinase inhibitors for the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as for cardiovascular and metabolic conditions; and modulators of G protein-coupled receptors. The company specializes in the fields of medicinal and analytical chemistry, biology, pharmacology, pharmacokinetics, pharmacodynamics, and clinical development.

PhotoThera

Series C in 2006
PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

PhotoThera

Series B in 2005
PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

Troika Networks

Series B in 2005
Troika Networks, Inc. specializes in providing integrated solutions for storage network data protection and management. Founded in 1998 and located in Westlake Village, California, the company offers a range of technologies that support disaster recovery, backup, and volume management. Its solutions are designed to be cost-effective and flexible, catering to the needs of enterprise customers through original equipment manufacturers and resellers globally. Troika Networks utilizes its proprietary Accelera Network Storage Services Platforms and ReadyPath Technology to enhance data protection and management capabilities, particularly in SAN-based environments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.